Palvella Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Palvella Therapeutics, Inc. (PVLA) had Debt Securities, Available-for-sale, Amortized Cost of $62.81 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $62.81M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $55.45M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $8.97M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $11.91M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $62.81M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $55.45M 10-Q · filed 2026-05-07 |
| 2023-12-31 | $8.97M 10-K · filed 2024-03-29 |
| 2023-09-30 | $11.91M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $9.94M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $8.64M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $20.61M 10-K · filed 2023-03-31 |
| 2022-09-30 | $21.32M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $26.53M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $16.55M 10-Q · filed 2022-05-11 |
| 2020-09-30 | $16.07M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $32.88M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $39.29M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $41.96M 10-K · filed 2021-03-31 |
| 2019-09-30 | $39.85M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $44.83M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $58.49M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $53.38M 10-K · filed 2020-03-13 |
| 2018-09-30 | $47.55M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $100.32M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $53.99M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |